Posted by Michael Wonder on 28 Jan 2026
Immix Biopharma receives US FDA breakthrough therapy designation for NXC-201
28 January 2026 - Breakthrough therapy designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology 2025 Annual Meeting.
Immix Biopharma today announced that the US FDA has granted breakthrough therapy designation to NXC-201 for the treatment of relapsed/refractory AL amyloidosis.
